Immunotherapies such as checkpoint inhibitors have revolutionized cancer therapy yet lead to a multitude of immune-related adverse events, suggesting the need for more targeted delivery systems. Due to their preferential colonization of tumors and advances in engineering capabilities from synthetic biology, microbes are a natural platform for the local delivery of cancer therapeutics. Here, we present an engineered probiotic bacteria system for the controlled production and release of novel immune checkpoint targeting nanobodies from within tumors. Specifically, we engineered genetic lysis circuit variants to effectively release nanobodies and safely control bacteria populations. To maximize therapeutic efficacy of the system, we used computational modeling coupled with experimental validation of circuit dynamics and found that lower copy number variants provide optimal nanobody release. Thus, we subsequently integrated the lysis circuit operon into the genome of a probiotic E. coli Nissle 1917, and confirmed lysis dynamics in a syngeneic mouse model using in vivo bioluminescent imaging. Expressing a nanobody against PD-L1 in this strain demonstrated enhanced efficacy compared to a plasmid-based lysing variant, and similar efficacy to a clinically relevant monoclonal antibody against PD-L1. Expanding upon this therapeutic platform, we produced a nanobody against cytotoxic T-lymphocyte associated protein -4 (CTLA-4), which reduced growth rate or completely cleared tumors when combined with a probiotically-expressed PD-L1 nanobody in multiple syngeneic mouse models. Together, these results demonstrate that our engineered probiotic system combines innovations in synthetic biology and immunotherapy to improve upon the delivery of checkpoint inhibitors. bacteria to grow within the hypoxic and necrotic tumor core (24) (25) (26) (27) . At the same time, microbiome research efforts have revealed the widespread prevalence of microbes within malignant tissue that do not cause infections or other long-term detrimental health effects (28, 29). Since bacteria are both inherently present and selectively grow in tumors, they provide a natural platform for the development of programmable therapeutic delivery vehicles.
SENTENCE SUMMARY
We designed a probiotic platform to locally deliver checkpoint blockade nanobodies to tumors using a controlled lysing mechanism for therapeutic release.
INTRODUCTION
Cancers exploit checkpoint signaling pathways by expressing ligands such as programmed cell death protein-ligand 1, PD-L1, which bind to the PD-1 receptor to inhibit the activation, expansion, and function of T cells and support immune evasion (1) (2) (3) . These inhibitory checkpoint blockade mechanisms have prompted the exploration of blocking monoclonal antibodies (mAbs) as therapeutics against these molecules. While anti-PD-L1 mAbs have achieved some level of tumor regression in ~30% of cancers like melanoma (4, 5) , they can also result in immune-related adverse effects (iRAEs), with up to 70% of patients experiencing a range of toxicity grades resulting in fatigue, skin rashes, endocrine disorders, or hepatic toxicities (6) (7) (8) (9) . Furthermore, combination therapies of anti-PD-L1/PD-1 mAbs and anti-cytotoxic T-lymphocyte associated protein-4 (CTLA-4) mAbs are more efficacious than monotherapies, but cause higher grade toxicities that lead to favoring of less efficacious monotherapies or eventual drug discontinuation (10, 11) . Moreover, iRAEs are often treated with steroids or other immunosuppressants that may comprise the antitumor response and subsequently affect the efficacy of checkpoint blockade antibodies (9, 12) .
Thus, there is a clear need for improved delivery of checkpoint blockade inhibitors to the tumor site to minimize adverse effects and shift the treatment preference towards combination therapy approaches.
Rapid development of genetic technologies has enabled the engineering of intelligent microbial delivery systems for therapeutic applications. Specifically, synthetic biology has generated numerous examples of genetic circuits controlling bacteria growth and gene expression (13) (14) (15) (16) (17) (18) (19) , allowing them to sense and respond to disease states of inflammation, infection, and cancer (20) (21) (22) (23) . Particularly for cancer, a multitude of studies have shown that systemic administration of bacteria results in their selective colonization of tumors, providing a unique opportunity for tumor drug delivery. This occurs primarily due to reduced immune surveillance along with the ability of end of the Nb for in vitro visualization and an Axe/Txe stability mechanism was cloned into the vector to prevent plasmid loss during bacterial replication ( Fig. S1a) (33) . The plasmid was transformed into the probiotic strain, E. coli Nissle 1917, containing a genomically integrated luxCDABE cassette for bacterial tracking in vivo (EcN-lux). E. coli Nissle 1917 was chosen as the therapeutic vehicle because of its proven safety, as it is currently prescribed for oral administration in humans, and for its ease in genetic manipulation (34).
Flow cytometry analysis ( Fig. 1b ) and immunofluorescence (Fig. S1b ) were used to confirm PD-L1 expression on CT26 cells, a colorectal cell line that has a modest antitumor response to PD-L1 mAb (35, 36) . To investigate the binding pattern of a previously uncharacterized PD-L1 Nb, bacterial lysate containing the probiotically-produced PD-L1 Nb was incubated on a monolayer of CT26 cells and an anti-HA mAb was used to probe for PD-L1 Nb binding. Imaging using fluorescence microscopy revealed a similar expression pattern to that of PD-L1 expression probed for by an anti-PD-L1 mAb (Fig. S1b ). To quantify binding kinetics of the PD-L1 Nb, multiple dilutions of bacterial lysate containing the PD-L1 Nb were co-incubated on a monolayer of CT26 cells with a constant concentration of fluorescently-tagged anti-PD-L1 mAbs known to bind to either the population lyses once a critical density is reached effectively releasing its therapeutic payload (21) . The SLC has been shown to aid in tumor-selective bacterial production, population limitation, and therapeutic release, serving multiple purposes critical for translational efforts. However, one drawback of the original SLC system is its reliance on plasmids. Since the quorum sensing genes and more importantly the lysis gene are cloned onto plasmid vectors, they can be lost or mutated during the bacterial growth cycle. To make this circuit more stable, we combined the original SLC two-plasmid system into a single operon, one-plasmid system that we then genomically integrated into EcN-lux. In this optimized system, the quorum sensing plux promoter drives transcription of both quorum sensing genes, luxR and luxI, and the phage-derived lysis gene, φ X174E ( Fig. 2a ).
Use of only one promoter and one terminator allowed for this smaller module to be more easily integrated and reduced repeat sequences that can lead to recombination.
While genomic integration of the SLC operon offers stability, it significantly reduces the copy number of quorum-sensing genes, prompting us to explore how this reduction would affect therapeutic efficacy. Therefore, we computationally modeled the behavior of each circuit variant to further understand the effect of copy number on lysis circuit dynamics. Using a system of ordinary differential equations, we modeled the dynamics of relevant variables in the lysing circuit: luxI, φ174E, bacteria number, the small molecule used for bacterial communication AHL (N-Acyl homoserine lactone), and therapeutic production. We first simulated the system to calculate two quantities: number of bacteria required to reach quorum for the first lysis event and time required to reach quorum ( Fig. 2b, c) . Here, we observed that decreasing copy number of the SLC circuit monotonically increased the number of bacteria required to reach a quorum threshold before lysing.
However, time to lysis displayed non-monotonic behavior, where the single copy variant produced a longer time to lysis than medium copy variants, but the high copy variant increased time to lysis again. This non-monotonic behavior is due to the higher level of basal lysis when high copies of the φ174E gene are present, resulting in slower growth, and thus longer time to reach quorum.
Further exploration of additional dynamic properties suggested that lower copy variants had a higher mean oscillation amplitude and frequency ( Fig. S2a , b).
The system's behavior at lower copy number variants motivated our exploration into the dynamics of therapeutic production as a direct function of population number over time, where we found that lower copy variants produced more therapeutic in a given period of time and at a faster rate compared to higher copy variants ( Fig. 2d, Fig. S2c, d ). Furthermore, the average rate of therapeutic production was time invariant, suggesting that this difference in therapeutic production rate was primarily a function of copy number. Given the differences in therapeutic production observed computationally, we sought to understand how our model could be used to predict bacterial dynamics in an in vivo setting. Previous studies have shown that bacterial growth kinetics are significantly slower in vivo, with the doubling time of the bacteria increasing from ~30 minutes in vitro to ~4 hours in vivo (26) . Using our model, we simulated oscillation frequency as a function of bacterial growth rate and copy number and found that lower copy number variants are more robust to a changing growth rate parameter ( Fig. 2e ). Together these findings suggest that the SLCint variant would result in maximal protein production across experimentally-relevant copy numbers.
To experimentally investigate system dynamics of the single operon SLC, we built a library of plasmid variants covering a range of copy numbers for the quorum sensing genes, including a single genomic integration of the operon into the φ80 site of the EcN-lux strain (SLC-int) ( Fig. 2a ).
Tracking of bacteria concentration over time in 96 well plates suggested that more copies of the lysing circuit leads to lysis at a lower bacteria concentration with a rapid decay relationship relating these two variables ( Fig. 2f, g) . Furthermore, the time it took each variant to reach quorum generally suggested that a lower copy number required more time to reach a critical density and the relationship exhibited non-monotonic behavior, consistent with our simulations (Fig. 2g ). To additionally visualize lysis events, the SLC-int variant was co-transformed with a constitutive plasmid (ptac:GFP) and imaged over time using fluorescence microscopy (Movie S1). Moreover, multiple oscillations for the SLC-int and SLC-P15A variants were observed by tracking the optical density over time in a plate reader ( Fig. S2e ).
We next tested whether the SLC-int strain demonstrated lysis behavior and predictable dynamics in vivo using a syngeneic CT26 hind flank tumor model ( Fig. 3a ). We monitored bacteria luminescence from the integrated luxCDABE cassette in tumors over time using an In-vivo Imaging System (IVIS) and observed a critical density at approximately 40 hours and population decay to a minimum level at 60 hours ( Fig. 3b ). Bacteria remaining then repopulated the system until the measurements ceased at the 84 hour time point. When compared to the original SLC two-plasmid system, the SLC-int system took twice as long to reach a critical density, similar to results obtained from our simulations.
Determining the optimal release mechanism for the PD-L1 Nb
Considering the varying dynamics of the integrated and plasmid-based systems, both the SLCint and SLC-p15A systems were engineered to produce the PD-L1 Nb. By western blot we were able to confirm production and release of the PD-L1 Nb into the supernatant and observed higher protein levels from the lowest copy SLC-int variant compared to the non-lysing EcN-lux strain transformed with the PD-L1 Nb plasmid at a 16 hour time point ( Fig. S3a ). We next explored the therapeutic efficacy in vivo of both the SLC-int and SLC-p15A copy number variants producing the PD-L1 Nb (SLC-int:PD-L1nb and SLC-p15A:PD-L1nb) in a CT26 hind flank syngeneic mouse model. After 2 weeks, a moderate therapeutic difference was observed, with the SLC-int:PD-L1nb variant resulting in slower relative tumor growth ( Fig. 3c ). As previously reported, some tumors treated with an anti-PD-L1 monotherapy have a greater response than other tumors within the same treatment group (35, 37) . Therefore, we looked at individual mean trajectories and found that for the SLC-int:PD-L1nb treated tumors, 2 of the 6 tumors grew much slower, with 1 tumor trending towards complete regression ( Fig. S3b ). More interestingly, when therapeutic treatment ceased at day 7 and tumors were left untreated for one week, the relative rate of tumor growth in the SLC-p15A:PD-L1nb variant group increased dramatically in comparison to those in the SLCint:PD-L1nb group resulting in a significant difference in tumor growth rate (Fig.3d, S3c ). This difference in growth rate when treatment stopped is likely to be a result of a more stable SLC-int bacterial system with less plasmid burden. Previous research suggests that increasing bacterial plasmid burden may increase plasmid instability or lead to mutations, which could ultimately affect the therapeutic efficacy of the strain (38) . Together these findings led us to choose the SLC-int strain as the release mechanism for the PD-L1 Nb therapeutic.
Comparison of the SLC-int: PD-L1nb system to anti-PD-L1 mAb
In the syngeneic hind flank mouse model of CT26, comparable therapeutic efficacy was observed for both the 10F.9G2 mAb and the SLC-int:PD-L1nb at day 4 ( Fig. 3e ). Analysis of individual mean tumor trajectories show that 1 out of 6 tumors in the 10F.9G2 mAb treated group showed minimal relative tumor growth, whereas at least 2 of the 8 tumors in the SLC-int:PD-L1nb treated group showed minimal growth or a reduction in tumor size ( Fig. S4 ). Furthermore, the distribution plot of the absolute tumor volumes for the 10F.9G2 mAb and the SLC-int:PD-L1nb were similar, with the average absolute tumor volume for the SLC-int:PD-L1 Nb treated group being slightly smaller than that of the 10F.9G2 mAb treated group (Fig. S4 ). While there was no striking difference in tumor sizes between the two anti-PD-L1 treatment groups, histological analysis indicated a higher dirty necrosis score in bacteria-treated tumors, suggesting that tumors treated with the SLC-int:PD-L1nb had less viable tissue and more neutrophils present in their tumor microenvironment compared to the anti-PD-L1 mAb group (Fig. 3f, Fig. S5 ).
We explored the versatility of a probiotically-produced PD-L1 Nb by comparing the therapeutic effects of an EcN-lux:SLC-PD-L1nb and the 10F.9G2 mAb in a Balb/c-4T1 syngeneic hind flank mouse model of triple negative breast cancer, where we observed severe toxicity and animal death after only three anti-PD-L1 mAb doses ( Fig.S6a, b ). After the second dose of the anti-PD-L1 mAb, the body condition of the mice visibly deteriorated with one-third of the mice losing more than 10% of their weight and subsequently remained untreated for the rest of the trial. After the third dose, the mice we had continued treating with the anti-PD-La mAb died and the remaining mice, having never recovered body condition after the second dose, were euthanized ( Fig. S6b ).
In contrast, mice receiving the EcN-lux control and EcN-lux-SLC:PD-L1nb had no change in body condition and appeared healthy throughout the trial. Toxicity to anti-PD-L1 monotherapy treatment has been previously reported in this breast cancer model (39) , but here we have demonstrated that a probiotically-produced PD-L1 Nb mitigates this observed toxicity. Furthermore, our engineered strain demonstrated moderate efficacy when compared to the WT EcN-lux control, suggesting that our engineered probiotic delivery system maintained efficacy while reducing toxicity ( Fig. S6c ).
Exploration of immunotherapeutic combination therapies
Due to its local delivery, bacterial therapy may be used to deliver combinations of therapeutics without increasing iRAEs. Therefore, we explored combinations to enhance therapeutic efficacy of our engineered SLC-int:PD-L1nb probiotic therapy in the CT26 model, where only moderate efficacy of the PD-L1 monotherapy was observed consistent with previous results in literature (35, 36) . The bacterially-expressed hemolysin exotoxin (hlyE) was chosen for combination with SLCint:PD-L1nb due to its ability to lyse mammalian cells and potentially release neoantigens that could then be recognized by infiltrating T cells. Furthermore, previous studies have demonstrated moderate efficacy of the hlyE as a monotherapy in mouse models of colorectal cancer (21) . The combination of SLC-int:PD-L1nb and EcN-lux producing hlyE (EcN-SLC-hlyE) significantly slowed tumor growth when compared to the individual therapies ( Fig. S7a) . A distribution plot of individual tumor volumes for each treatment group indicates that tumors with the combination therapy were smaller than those treated with the monotherapies. (Fig. S7b ). The overall effect of the combination therapy is more apparent in the individual trajectories, where more mice receiving the combination therapy demonstrated slowed tumor growth over time ( Fig. S7c ). Lastly, since increased toxicity is observed when immunotherapeutics are used in combination, we tracked body weight of the mice as a proxy for mouse health throughout the trial and saw no significant changes in body weights between treatment groups at the end of the trial (Fig. S7d ).
Combination of the SLC:PD-L1nb and EcN-SLC-hlyE therapeutics suggest that the PD-L1 Nb therapeutic platform can be further maximized through combination therapy approaches. Clinically, anti-CTLA-4 mAbs are frequently used in combination with anti-PD-L1 mAbs (40, 41) . Therefore, to make our platform more generalizable as a checkpoint blockade treatment option, we engineered a microbial cocktail that could also block the interaction between CTLA-4 and its associated ligands (42, 43) . A Nb against CTLA-4 was chosen from the RCSB Protein Data Bank and its sequence was cloned onto the same plasmid vector used to express the PD-L1 Nb (Fig.   S8a ). In the CT26 mouse model, the SLC-int:CTLA-4nb monotherapy was moderately efficacious and demonstrated similar efficacy to that of the anti-CTLA-4 mAb ( Fig. S8b ). While the therapeutic response for tumors treated with SLC-int:CTLA-4nb was only modest, less toxicity was observed in these mice compared to the anti-CTLA-4 mAb group, with the mice receiving EcN-lux only and the SLC-int:CTLA-4nb increasing in body weight at a faster rate than those receiving the anti-CTLA-4 mAb. Over the course of two weeks, the average weight of mice treated with the anti-CTLA-4 mAb had increased by ~10%, while the average weight of the SLC-int:CTLA-4nb mice had increased by ~30% ( Fig. S8c ). Additionally, treatment with the SLC-int:CTLA-4nb induced the production of more IFNγ in the tumor microenvironment when compared to the anti-CTLA-4 mAb and the EcN-lux control ( Fig. S8d ). An increase in pro-inflammatory cytokines like IFNγ may suggest an increase in T cell infiltration and proliferation, thereby providing further rationale for combining the SLC-int:CTLA-4nb and SLC-int:PD-L1nb therapeutics.
To further explore efficacy in the CT26 model, we treated tumors with a combination of the checkpoint blockade Nbs (Nb cocktail) against PD-L1 and CTLA-4 and observed a significant reduction in the absolute tumor volume compared to the monotherapies (Fig. 4a ). Furthermore, mouse body weight was tracked throughout the trial and no significant weight changes were observed ( Fig.   S9a ). To explore the versatility of our combinatorial Nb platform to other models, we tested the Nb cocktail in a syngeneic A20 lymphoma model, where previous literature reports therapeutic efficacy when treated with combination therapies including checkpoint inhibitors (35). We observed a striking efficacy of the Nb cocktail compared to individual SLC-int:CTLA-4nb and SLCint:PD-L1nb monotherapies, with 3 out of 5 tumors completely regressing and the remaining two tumors showing significant size reduction ( Fig. 4b ). Moreover, no toxicity was observed and the mice appeared to be healthy and maintain their body condition throughout the trial (Fig. S9b ). To further understand the underlying immune response of the observed therapeutic effect, we interrogated the immunophenotype of extracted A20 tumors by flow cytometry and observed a decrease in the the population of regulatory T cells (Tregs, CD4 + FOXP3 + ) in tumors treated with the Nb cocktail ( Fig. 4c ). Furthermore, there was an increase in the proliferation of conventional CD4+ T cells (CD4 + FOXP3 -Ki67 + ) in the Nb cocktail-treated tumors, suggesting that the shift in favor of responsive T cells and decrease in immunosuppressive Tregs may result in a more robust immune response and mediate the therapeutic effect observed (Fig. 4d ).
DISCUSSION
Here, we have demonstrated the first instance of PD-L1 and CTLA-4 antagonists being expressed by bacteria, which allowed for local therapeutic production and minimized toxicity in multiple syngeneic mouse models. Furthermore, we have characterized novel PD-L1 and CTLA-4 Nbs that can be adapted into other biological circuits and we have optimized their therapeutic release using a genomically-integrated lysing circuit, thereby reducing possible horizontal gene transfer for translational studies. This circuit also serves as a biocontainment measure to confine the bacterial population to the tumor site thereby minimizing the risk of systemic iRAEs.
The SLC-int:Nb systems demonstrated comparable therapeutic efficacy to analogous clinically relevant mAbs and combining the SLC-int:PD-L1 Nb with a bacterially-expressed hemolysin exotoxin led to greater therapeutic efficacy than either monotherapy. Furthermore, the combined Nb cocktail demonstrated tumor shrinkage in the CT26 model and resulted in complete tumor regression in the A20 model. We hypothesize that the synergistic effect of this combination therapy might be a result of fewer immunosuppressive Tregs and an increase in the proliferation of CD4+ helper T cells. Moreover, SLC-int:CTLA-4nb led to more detectable IFNγ levels at the tumor site, which could act cooperatively with the SLC-int:PD-L1nb by supporting increased infiltration of immune cells into the tumor microenvironment. Additionally, the production of such cytokines is specifically advantageous for CT26 tumors because colorectal cancers are considered "cold" due to overproduction of prostaglandins that dampen the immune response (44) . For this reason, these tumors have only demonstrated modest responses to checkpoint blockade. Therefore, administration of checkpoint blockade nanobodies in vehicles that might lead to more immune cell recruitment could potentially enhance therapeutic responses which would be otherwise difficult to attain for "cold" cancers. To understand the mechanism underlying the therapeutic effects of the SLC-int:Nb system on these types of cancers, further investigation into the immune landscape after treatment will be required.
Cancer immunotherapies are often more effective in combination with other anticancer agents.
Therefore, future iterations of the SLC-int system will be programmed to produce a wide variety of immunotherapeutics that can then be tested in combination with the SLC-int:Nb platform. Microbial-based therapeutic platforms are highly modular and optimal for the rapid production of multiple drugs that can then be delivered as a cocktail. Furthermore, to make the system more clinically relevant, other routes of therapeutic administration will be considered. With this in mind, we developed the SLC-int:Nb system in the probiotic strain, E.coli Nissle 1917, which has been shown to colonize liver metastases when delivered orally (45), thus offering a more translational route of therapeutic delivery for more advanced metastatic disease.
All together, we have built a stable biological circuit integrated into a probiotic with therapeutics analogous to the current treatment standard for optimization towards clinical translation. The SLCint:Nb system will help advance the cancer immunotherapy field by providing a delivery vehicle in which combination therapies can be easily explored and toxicities minimized for a broader range of cancer patients.
MATERIALS AND METHODS

Study Design
The goal of this study was to develop a probiotic platform that enables the controllable release and effective delivery of checkpoint blockade Nbs within tumors. Due to the preferential growth of microbes within the tumor core, we hypothesized that this delivery platform would reduce toxicities and allow for the delivery of safer and more effective combination therapies. A lysing mechanism was used to release the therapeutic and characterization of these therapeutics, including binding kinetics was established in vitro with the CT26 cell line. We then sought to test our delivery system in vivo, where all studies were performed on syngeneic hind flank mouse models of CT26, 4T1, or A20 cancers. All mice were randomized prior to treatment and received injections of either monotherapies (SLC-int:PD-L1nb, SLC-hlyE, SLC-int:CTLA-4nb) or combinations of therapies, ensuring that the final concentration of bacteria injected was the same. Caliper measurements were used to track tumor volume, and mouse weight was monitored as a proxy for mouse health.
Statistical analysis and sample sizes were determined from previous studies (21, 26, 45) . Further details on sample size and replications (technical or biological) are provided in the figure legends.
Plasmid and Strains
Our circuit strains were cultured in LB media with their respective antibiotics (SC101*variant:
100µg ml -1 ampicillin, p15A variant: 100µg ml -1 spectinomycin, ColE1: 100µg ml -1 spectinomycin, and all with 50µg ml -1 spectinomycin and kanamycin for strains also transformed with PD-L1 therapeutic plasmid) with 0.2% glucose, in a 37 o C shaking incubator. CT26 and 4T1 mammalian cells were purchased from ATCC and cultured in RPMI supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. A20 cells were purchased from ATCC and cultured in RPMI supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin and 0. 
Immunofluorescence and Characterization
Collecting PD-L1 Nb protein
Non-lysing bacterial strains containing the PD-L1 Nb therapeutic plasmid were grown in a 50mL LB culture with appropriate antibiotics to an optical density of 0.6 then centrifuged at 3000 rcf for 5 minutes. The bacterial pellet was resuspended in 5mL of RPMI media. Samples were frozen at -80 o C and thawed in a 30 o C incubator 5 times and centrifuged at 3000 rcf for 5 minutes to remove bacterial debris. 1mL of the resulting lysate was then filtered through a 0.2 micron filter. Single-stains and isotype controls were used for compensation of the dual stain. FlowJo was used for all data analysis.
Flow cytometry
Microscopy
For microscopy, 1x10 6 CT26 cells were stained on a poly-l-lysine coated glass flat bottom plate with appropriate antibodies for detection of PD-L1 expression (10F.9G2 clone). In a separate experiment, full bacterial lysate containing PD-L1 Nb was incubated on the monolayer of CT26 cells and probed with a pre-conjugated anti-HA antibody. A Nikon Eclipse Ti microscope was used for all microscopy and FIJI was used for any post-image analysis.
Characterization of PD-L1 Nb Expression and Release
To determine protein expression and functionality of the HA tag, PD-L1 Nb protein was released using the freeze/thaw method described above. A western blot was use for protein visualization and was probed for 1hr with the primary anti-HA antibody (1:800) and 1hr with a rat HRP (1:4000) at room temperature. Protein was detected using a chemiluminescent substrate.
In vivo Studies
Tumor models
Animal experiments were performed on 6-8 week old female BALB/C mice from Taconic with bilateral subcutaneous hind flank tumors from an implanted mouse colorectal cancer cell line CT26, mouse lymphoma cell line A20, or a mouse breast cancer cell line, 4T1. Tumor cells were prepared for implantation at a concentration of 5e7 cells/ml in RPMI without phenol red. Cells were implanted at 100uL per flank, with each implant consisting of 5x10 6 cells. Tumors grew for approximately 10 days or until the diameter was 4-10mm in diameter or volume was ~200mm 3 for CT26 and 4T1 tumors and ~150mm 3 for A20 tumors. All mice were randomized prior to treatment.
Bacteria growth and therapeutic administration
Bacterial strains were grown overnight in LB media containing appropriate antibiotics and 0.2% glucose for less than 12 hours. The overnight was subcultured at a 1:100 dilution in 50mL of fresh media with antibiotics and glucose and grown until an OD of approximately 0.05 to prevent bacteria containing SLC operon from reaching quorum. Bacteria were spun down at 3000 rcf and washed 3 times with sterile ice-cold PBS. Bacteria were delivered intratumorally at a concentration of 5e7 cells/ml in PBS with a total of 30-40uL injected per flank every 3-4 days (OD of 0.1 is equivalent to 1e8 cells/mL). The PD-L1 mAb and the CTLA-4 mAb were injected intraperitoneally at a concentration of 200ug/mouse and 100ug/mouse respectively.
Tumor and bacteria monitoring in vivo
CT26 and 4T1 tumor volumes were quantified using calipers to measure length, width, and height of each tumor with volumes being reported as LxWxH. A20 tumors were measured as (LxW)/2. Tumors were measured every 3 to 4 days and mouse weight was tracked to monitor overall mouse health. All bacterial strains used were luminescent, which could be measured with the In Vivo Imaging System. Living Image software was used for luminescent quantification.
Histology
Tumors were extracted, fixed in 10% formalin, and sent to the Histology and Imaging Core at the University of Washington, where the tissue was processed and Haemotoxylin and Eosin stained.
The pathologist blinded to sample treatments manually scored the samples for dirty necrosis (0 = not present, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe, abscess like)
Cytokine Analysis
Tumors were extracted from mice on day 14 following initial treatment. After one snap-freeze cycle, tumors were mechanically lysed in complete lysis buffer (1x Protease Inhibitor cocktail, Sigma Aldrich Cat: P27using a gentleMACS Dissociator.14-1BTL; EMD Millipore lysis buffer (Cat: 43-040) using a gentleMACS tissue dissociate. Once fully dissociated, the tumor homogenates were centrifuged for 10min at 10,000g to clear debris. The lysate was spun for 5min at 5,000g.
Pre-cleared lysates were stored at -80C until analysis by Luminex Multiplex Assay. A Bradford colorimetric assay was used to normalize protein concentrations and 35ug lysate in 25uL volume was analyzed in the Luminex Multiplex Assay (EMD Millipore) according to the manufacturer's protocol.
Statistical Analysis
Statistical tests were calculated in GraphPad Prism 7.0. The details of the statistical tests are indicated in the respective figure legends. Where data was assumed to be normally distributed, values were compared using a one-way ANOVA for single variable or a two-way ANOVA for more than one variable with a Bonferroni post-test applied for multiple comparisons. For categorical data comparisons, data was assumed to be nonparametric and a Mann Whitney U Rank test was used for single variable, two group comparisons. 
SUPPLEMENTARY MATERIALS
Mathematical Model
Movie S1: Visualization of SLC-int lysis.
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Mathematical Model
We built upon the ordinary differential equation model explored in the original sycnhrionized lysis circuit system (19) . The following set of ordinary differential equations were derived to describe the bacterial population number (N, equation [1] ), total extracellular AHL (H, equation [2] ), intracellular concentrations of the lysis protein E (L, equation [3] ), intracellular concentrations of the LuxI protein (I, equation [4] ), and intracellular concentrations of the PD-L1 Nb protein (P, equation [5] ). In this system, bacteria grow logistically at a rate of µ N to a maximum capacity, N 0 and lyse once at quorum. AHL is produced at a rate proportional to bacterial population and is cleared out at a rate of µ. The lysis protein is produced at a rate proportional to copy number and has a basal degradation (γ L ) and is also diluted as the bacterial population grows (µ g ). The luxI protein has similar dynamics, but is further degraded by ClpXP machinery (γ c ). The therapeutic protein production is proportional to bacteria number and has basal degradation (γ p ) and is diluted as the bacterial population grows (µ g ). Internal production of LuxI and lysis protein is described by P lux (equation [6] ) and the rate of cell degradation due to lysis is described by the hill function, γ N (equation [7] ) . h 0 =5, b=20, µ g = 1.5, L 0 = 8, n=2, m=4. γ L = 1.5, K =0.05, γ I = 5, γ C = 12, N 0 =10.
Movie S1: Visualization of SLC-int lysis. The EcN-lux:SLC-int strain was transformed with a ptac:sfGFP plasmid. Bacteria were seeded onto a 96 well glass bottom plate and timelapse was used to capture GFP fluorescence change over time at 10X magnification.
